The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of BP1001 (Liposomal Grb2 Antisense) in patients with hematologic malignancies.
 
Maro Ohanian
Research Funding - Bio-Path Holdings, Inc (Inst)
 
Farhad Ravandi
Honoraria - Amgen; Pfizer; Seagen; Sunesis Pharmaceuticals
Consulting or Advisory Role - Amgen; Seagen; Sunesis Pharmaceuticals
Research Funding - Amgen; Bristol-Myers Squibb; Merck; Seagen; Sunesis Pharmaceuticals
 
Gautam Borthakur
No Relationships to Disclose
 
Guillermo Garcia-Manero
No Relationships to Disclose
 
Michael Andreeff
Stock and Other Ownership Interests - Aptose Biosciences; Oncoceutics; Reata Pharmaceuticals; Roche/Genentech
Honoraria - Roche/Genentech
Consulting or Advisory Role - Aptose Biosciences; Oncoceutics
Research Funding - Daiichi Sankyo; Roche/Genentech
Patents, Royalties, Other Intellectual Property - Daiichi Sankyo; Reata Pharmaceuticals
Travel, Accommodations, Expenses - Aptose Biosciences; Oncoceutics
 
Elias Jabbour
Research Funding - Amgen (Inst); Novartis (Inst); Pfizer (Inst)
 
Yesid Alvarado
No Relationships to Disclose
 
Marina Konopleva
Stock and Other Ownership Interests - Reata Pharmaceuticals
Honoraria - Abbvie; Calithera Biosciences; Genentech
Consulting or Advisory Role - AbbVie
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Cellectis (Inst); Genentech (Inst); Lilly (Inst); Novartis (Inst); Stemline Therapeutics (Inst)
 
Miranda Lim
No Relationships to Disclose
 
Sherry Pierce
No Relationships to Disclose
 
Susan Mary O'Brien
Honoraria - Celgene; Gilead Sciences; Janssen; Pfizer; Pharmacyclics; ProNAi; Regeneron
Consulting or Advisory Role - Amgen; Celgene; CLL Global Research Foundation
Research Funding - Acerta Pharma; Gilead Sciences; Regeneron
Travel, Accommodations, Expenses - Celgene; Gilead Sciences; Janssen; Regeneron
 
Ana Tari Ashizawa
Employment - Bio-Path Holdings, Inc
Stock and Other Ownership Interests - Bio-Path Holdings, Inc
Consulting or Advisory Role - Bio-Path Holdings, Inc
Patents, Royalties, Other Intellectual Property - Bio-Path Holdings, Inc
 
Srdan Verstovsek
No Relationships to Disclose
 
William G. Wierda
Consulting or Advisory Role - Abbvie; Celgene; Emergent BioSolutions; Genentech/Roche; Genzyme; Gilead Sciences; GlaxoSmithKline/Novartis; Merck; Pharmacyclics; Sanofi
Research Funding - Abbvie; Acerta Pharma; Emergent BioSolutions; Gilead Sciences; GlaxoSmithKline/Novartis; Janssen; Juno Therapeutics; Karyopharm Therapeutics; Kite, a Gilead company; Roche
 
Jorge E. Cortes
Consulting or Advisory Role - Ambit BioSciences; Amphivena Therapeutics; ARIAD; Astellas Pharma; BiolineRx; Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Ambit BioSciences (Inst); ARIAD (Inst); Arog (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celator (Inst); Celgene (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Teva (Inst)